C
Charles D. Blanke
Researcher at University of British Columbia
Publications - 106
Citations - 17049
Charles D. Blanke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 33, co-authored 87 publications receiving 16100 citations. Previous affiliations of Charles D. Blanke include University of Michigan & Oregon Health & Science University.
Papers
More filters
Journal Article
Perioperative treatment of gastrointestinal stromal tumors.
Gustavo Dos Santos Fernandes,Charles D. Blanke,Daniela Reis Joaquim de Freitas,Rodrigo Guedes,Paulo M. Hoff +4 more
TL;DR: Neoadjuvant treatment often decreases the tumor size, allowing a less morbid surgery, appears to be safe and beneficial for some patients, and therefore deserves further study.
Journal ArticleDOI
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
Stan G. Louie,Ely B,Heinz-Josef Lenz,Kathy S. Albain,Carolyn C. Gotay,Coleman D,Derek Raghavan,Derek Raghavan,Anthony F. Shields,Philip J. Gold,Charles D. Blanke +10 more
TL;DR: The results suggest that metabolic enzymes involved in converting capecitabine metabolites are not altered by age, and carboxylesterase and cytidine deaminase activity was similar between the two age groups.
Journal ArticleDOI
Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may.
TL;DR: Two articles published in this issue of Journal of Clinical Oncology address different methods of using antibody therapy in mCRC and answer some important questions but also potentially raise even more.
Journal ArticleDOI
Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
Charles D. Blanke,Daniel M. Huse +1 more
TL;DR: 2nd-line sunitinib appears to be cost effective in patients with advanced GIST who are intolerant/resistant to imatinib, and inconsistency among the studies evaluated with regard to methodologies, countries of origination, and patient demographics.
Journal ArticleDOI
Erratum: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132 (Annals of Surgical Oncology (2011) DOI: 10.1245/S10434-011-2190-5)
Dian Wang,Qiang Zhang,Charles D. Blanke,George D. Demetri,Michael Heinrich,James C. Watson,John P. Hoffman,Scott H. Okuno,John M. Kane,Margaret von Mehren,Burton L. Eisenberg +10 more
TL;DR: This research presents a novel, scalable, scalable and scalable approach to tumorigenicity that is able to assess the impact of chemotherapy on individual cells and provide a prognosis for individual patients.